

GENART Technologies, Inc.

- The Art of Caring -

Harry F. Crevecoeur, M.D.

Valley Stream, NY 11580
Email: HCrevecoeurMD1@Genart.net

November 8, 2010

Former President Bill Clinton

55 West 125th Street
14th Floor
New York, NY 10027-4526

Re: The Ideal HIV Vaccine

Honorable William Clinton:

As you probably know, the NIH does not have any grant available for *THERAPEUTIC HIV vaccine* (although they do have many grants for *preventative HIV vaccines*).

I am writing this letter to request your support and the opportunity to provide you and your trusted doctors/scientists detailed information on an ideal HIV vaccine that we, at Genart Technologies, designed to be: effective (*with cross-clade neutralization of HIV-1*), safe, affordable, **therapeutic and preventative**. In a speech at Morgan State University in 1997, you committed us to developing an AIDS vaccine within 10 years, meaning a deadline of 2007. I am pleased to inform you that as of August 1, 2007, at Genart Technologies, we discovered **promising evidence that the HIV pandemic can be solved** with the HIV vaccine we are developing.

Despite limited funding, our novel HIV vaccine design enabled us to triumph where pharmaceutical giants like SmithKline-Beacham, Merck and others have either failed or given up. Although I respect any skepticism which may dominate your impressions at this time, **please allow me to invite you to accept the notion that, yes, a “CURE” for HIV is indeed possible - and now finally in sight.**

By translating the conserved entity of HIV's gp120 from 3-D configuration to linear formats, we helped conquer the most challenging issues in HIV vaccine design: broad-spectrum coverage with inter- and intra-clade neutralization of HIV-1.... As complex as it may sound, I submit to you that our method and our vaccine design hold the most promising solution to the HIV problem. I am confident that our HIV vaccine design, with your support, can succeed **in less than five years** and deliver the ground-breaking vaccine so desperately anticipated in the world.

Please note that efficacy in the therapeutic arm for this vaccine can be demonstrated in weeks or months as opposed to that of the preventative arm which will require years.

In our commitment to keep the final price of this life-saving vaccine affordable, we are seeking a collaborative agreement with the NIH to help finalize the pre-clinical studies and complete the clinical trials. We humbly ask if you would join your voice to our efforts and help make this “impossible dream” a reality soon.

This is a revolution in immunology and it’s crucial that the NIH take notice of our novel technology in order to help win the fight against HIV.

As you know, the world depends greatly on American ingenuity: When “The Impossible” is actually “What needs to be done,” we get it done. We can do this. The ideal HIV vaccine: effective, safe, affordable, preventative and therapeutic. Please allow us the opportunity to provide you and your trusted doctors/scientists detailed information on our HIV vaccine design and development strategies. Though yet unpublished, our information is covered by U.S. and international patents. We can arrange a conference at your convenience to demonstrate our interesting findings.

Sincerely,

Harry F. Crevecoeur, MD
GENART Technologies, Inc.

CC:	Dr. Margaret Johnston,	<i>National Institutes of Health</i>
	Dr. Anthony Fauci,	<i>National Institutes of Health</i>
	Carl W. Dieffenbach, Ph.D.	<i>Director, Division of AIDS, NIAID, NIH, DHHS</i>
	Anthony Conley, Ph.D.	<i>Program Officer, NIAID, NIH, DHHS</i>
	1 st Lady Michelle Obama	
	Bruce Agins, MD	<i>New York State DOH AIDS Institute, Medical Director</i>
	Mathieu Eugene, MD	<i>New York City Council</i>
	Antonio Martin, M.S.	<i>Kings County Hospital Center, Senior Vice President</i>
	Adele Fleteau, M.S.	<i>Kings County Hospital Center, Senior Assoc. Director</i>
	Harvey Lawrence,	<i>Brownsville Multi-Service Family Health Center, CEO</i>
	William F. Boyland, Jr.	<i>New York State Assembly</i>
	Richard Strauss, Esq.	<i>GENART Technologies, Inc.</i>
	Gary Strauss, D.Phil.	<i>Pb2Au Biotech Development</i>
	Bill Gates	<i>Gates Foundation</i>
	Oprah Winfrey	<i>Oprah</i>

Enclosures: